REGENERON PHARMACEUTICALS ($REGN) posted quarterly earnings results on Tuesday, April 29th. The company reported earnings of $8.22 per share, missing estimates of $9.33 by $1.11. The company also reported revenue of $3,028,700,000, missing estimates of $3,411,165,600 by $-382,465,600.
You can see Quiver Quantitative's $REGN stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
REGENERON PHARMACEUTICALS Insider Trading Activity
REGENERON PHARMACEUTICALS insiders have traded $REGN stock on the open market 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $REGN stock by insiders over the last 6 months:
- MARION MCCOURT (EVP Commercial) sold 1,000 shares for an estimated $844,610
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
REGENERON PHARMACEUTICALS Hedge Fund Activity
We have seen 583 institutional investors add shares of REGENERON PHARMACEUTICALS stock to their portfolio, and 708 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- FMR LLC removed 2,163,122 shares (-20.9%) from their portfolio in Q4 2024, for an estimated $1,540,856,694
- CAPITAL WORLD INVESTORS removed 1,519,407 shares (-35.3%) from their portfolio in Q4 2024, for an estimated $1,082,319,188
- CAPITAL INTERNATIONAL INVESTORS added 1,390,534 shares (+41.6%) to their portfolio in Q4 2024, for an estimated $990,519,084
- PRICE T ROWE ASSOCIATES INC /MD/ added 810,144 shares (+63.5%) to their portfolio in Q4 2024, for an estimated $577,089,875
- CAPITAL RESEARCH GLOBAL INVESTORS removed 644,868 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $459,358,822
- MASSACHUSETTS FINANCIAL SERVICES CO /MA/ removed 499,031 shares (-97.0%) from their portfolio in Q4 2024, for an estimated $355,474,752
- AMUNDI added 487,489 shares (+45.8%) to their portfolio in Q4 2024, for an estimated $347,253,039
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
REGENERON PHARMACEUTICALS Congressional Stock Trading
Members of Congress have traded $REGN stock 8 times in the past 6 months. Of those trades, 1 have been purchases and 7 have been sales.
Here’s a breakdown of recent trading of $REGN stock by members of Congress over the last 6 months:
- REPRESENTATIVE ROBERT BRESNAHAN sold up to $15,000 on 02/25.
- REPRESENTATIVE JULIE JOHNSON has traded it 2 times. They made 1 purchase worth up to $15,000 on 01/15 and 1 sale worth up to $15,000 on 02/12.
- REPRESENTATIVE JOSH GOTTHEIMER has traded it 3 times. They made 0 purchases and 3 sales worth up to $45,000 on 01/24, 11/29, 11/19.
- REPRESENTATIVE JONATHAN L. JACKSON has traded it 2 times. They made 0 purchases and 2 sales worth up to $65,000 on 11/13, 11/01.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
REGENERON PHARMACEUTICALS Analyst Ratings
Wall Street analysts have issued reports on $REGN in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Cantor Fitzgerald issued a "Overweight" rating on 04/22/2025
To track analyst ratings and price targets for REGENERON PHARMACEUTICALS, check out Quiver Quantitative's $REGN forecast page.
REGENERON PHARMACEUTICALS Price Targets
Multiple analysts have issued price targets for $REGN recently. We have seen 7 analysts offer price targets for $REGN in the last 6 months, with a median target of $903.0.
Here are some recent targets:
- Carter Gould from Cantor Fitzgerald set a target price of $695.0 on 04/22/2025
- John Newman from Canaccord Genuity set a target price of $850.0 on 04/22/2025
- An analyst from BMO Capital set a target price of $903.0 on 03/14/2025
- Christopher Raymond from Piper Sandler set a target price of $1195.0 on 11/01/2024
- Andrew Berens from Leerink Partners set a target price of $880.0 on 11/01/2024
- Cory Kasimov from Evercore ISI set a target price of $1170.0 on 10/31/2024
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
